University of Sussex

File(s) under permanent embargo

P200 The clinical, utility and economic benefits of securing minimal important difference in asthma control test using a novel tool: the a.b.o.v.e. asthma (achieving-better-outcomes-and-value-for- everybody-in-asthma)

conference contribution
posted on 2023-06-09, 09:03 authored by A Manfrin, M Tinelli
Introduction and objectives: Asthma accounts for an economic loss of €72 billion annually in the 28 countries of the European Union with a monetised value of DALYs cost of €38 billion. One of the key priorities in asthma management is achieving asthma control. It is crucial to understand whether providing a minimally clinical important difference (MID) of the asthma control test (ACT) score can bring better clinical, utility and economic outcomes. Aim: To test whether the A.B.O.V.E. ASTHMA (Achieving-Better-Outcomes-and-Value-for-Everybody-in-Asthma) tool works in terms of securing the MID in ACT and, in doing so, we can provide positive outcomes for patients, payers, providers and policy makers. Methods: Using the data obtained from the Italian Medicines Use Review (I-MUR) cluster randomised controlled trial (C-RCT; 2014-2015) involving 1,263 asthma patients and 283 pharmacists in Italy, we tested whether A.B.O.V.E. ASTHMA was able to (1) link a clinical outcome (ACT score) to economic and utility dimensions; (2) secure a MID improvement in ACT and the outcomes attached in terms of cost savings for the healthcare provider and gains in health utility (% of being in perfect health). Results: Data from the C-RCT showed that after receiving the A.B.O.V.E. ASTHMA intervention, patients improved their asthma control, assessed by the ACT, shifting from not controlled (RED; ) towards partially controlled (YELLOW, ), and fully controlled (GREEN, ) groups. Asthma control improved in the vast majority of patients (median ACT score was 19 at baseline, 20 at 3-month and 21 at 6-month post intervention). The number of patients who were on MID target and reached the GREEN group ( ) at 3 and 6 months were 129 (15.8%) and 162 (19.9%) respectively. The overall annual cost savings per 1,000 patients attached to the shift towards the MID target was equal to: 346,012 euros (NHS) at 3 months and increased to 425,483 euros (NHS) at 6 months (see Table). Health utility gains were equal to 0.9 and 0.29 years in full health, respectively. Conclusions: The A.B.O.V.E. ASTHMA tool can secure MID in ATC and, in doing so, better outcomes in terms of clinical, utility and economic results.


Publication status

  • Published

File Version

  • Published version






BMJ Publishing Group





Article number


Event name

British Thoracic Society Winter Meeting 2017

Event location

QEII Centre Broad Sanctuary Westminster London SW1P 3EE

Event type


Event date

6 to 8 December 2017

Book title

External influences on asthma

Department affiliated with

  • Biochemistry Publications

Full text available

  • No

Peer reviewed?

  • Yes

Legacy Posted Date


First Compliant Deposit (FCD) Date


Usage metrics

    University of Sussex (Publications)


    No categories selected


    Ref. manager